BioCentury
ARTICLE | Financial News

Canaan, F-Prime back pain play Nocion with $27M round

April 17, 2019 9:54 PM UTC

Nocion announced Wednesday $27 million in series A funds to develop non-addictive analgesics that avoid the numbness and paralysis of sodium channel blockers like lidocaine.

Nocion Therapeutics Inc. (Cambridge, Mass.) thinks its compounds can replace opioids in a range of disease areas, including its lead indication, cough (see "Targeting Pain Neurons and Nothing Else")...